Goldman Sachs Sees Heavy Upside in United Therapeutics (UTHR) With Limited Risk

Goldman Sachs reiterated their Buy rating and $82 price target on United Therapeutics Corp. (NASDAQ: UTHR) following underperformance after the June release of data from the first Phase 3 trial of a new oral formulation of the company’s franchise PAH drug Remodulin.

The firm remains confident that oral Remo will succeed in Phase 3 and reach the growing $3 billion PAH market. They note a number of reasons why we expect oral Remo to succeed in C2 in August/September.

If oral Remo succeeds, as expected, shares should trade in line or above a $70 fundamental value, which excludes an M&A premium. If it fails shares are still worth $58, or above current levels.

For more ratings news on United Therapeutics Corp. click here and for the rating history of United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $56.64 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lowe's (LOW) PT Lowered to $275 at Guggenheim
• Freedom Broker Upgrades Walmart (WMT) to Buy
• HomeTrust Bancshares (HTB) PT Raised to $57 at Stephens